With late-stage clinical results hitting the tape, Esperion Therapeutics Inc (NASDAQ: ESPR) is flying in the pre-market hours this morning. With the reaction in mind, chances are that you guessed that the results were positive, and they were overwhelmingly so. With the results in mind, excited investors are sending the stock running for the top. Today, we’ll talk about:
- The clinical results;
- what we’re seeing from ESPR as a result; and
- what we’ll be watching for with regard to the stock ahead.
ESPR Heads For The Top On Late-Stage Clinical Results
As mentioned above, Esperion is having a great start to the trading session this morning after announcing positive clinical results. In a press release issued early this morning, the company said that it has completed the Phase 3 LDL-C Lowering Development Program centered around bempedoic acid. The reults of the study proved to be positive.
In the release, ESPR reminded investors that the clinical trial included 3,621 patients at high risk for cardiovascular events who are taking statin yet required additional lowering of LDL-C. The primary endpoint of the study as well as other key secondary endpoints were reached.
In terms of efficacy, bempedoic acid led to a reduction of an additional 18 to 31% with the intent to treat population seeing additional LDL reductions between 17 and 28%. Also, reductions of 19 to 33% were seen in high-sensitivity C-reactive protein, an improtant creator of the underlying inflammation associated with heart disease. Finally, the treatment led to reductions in hemoglobin A1c of between 0.19 and 0.31% when compared to placebo in a subset of 1002 patients with diabetes.
On the safety and tolerability side, ESPR had more good news to offer. Through the study, bempedoic acid proved to be safe and well tolerated among the patient population.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news leads to moves. When it comes to Esperion Therapeutics, the news proved to be overwhelmingly positive. After all, positive late-stage study results likely mean that a New Drug Application with the United States Food and Drug Administration is on the horizons, pushing the company one step closer to commercialization of this asset. So, it comes as no surprise that excited investors are pushing the stock on a run for the top this morning. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currnetly (7:05), ESPR is trading at $46.00 per share after a gain of $4.12 per share or 9.84% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on ESPR. In particular, we’re interested in following the story surrounding the continued development of bempedoic acid as the treatment seems to be yielding incredibly positive results and may be a short way away from commencement of a New Drug Application with the FDA. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!